• 1
    Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469478.
  • 2
    World Health Organization. The European Health Report. Copenhagen: WHO Regional Office for Europe. WHO Regional Publications, European Series, No. 97.
  • 3
    Hooi LN. What are the clinical factors that affect quality of life in adult asthmatics? Med J Malaysia 2003;58:506515.
  • 4
    Juniper EF. Effect of asthma on quality of life. Can Respir J 1998;5(Suppl. A):77A84A.
  • 5
    Adams RJ, Wilson DH, Taylor AW, Daly A, Tursan d’Espaignet E, Dal Grande E et al. Psychological factors and asthma quality of life: a population based study. Thorax 2004;59:930935.
  • 6
    European Respiratory Society and the European Lung Foundation. European lung white book. Brussels, Belgium: European Respiratory Society and the European Lung Foundation, 2003.
  • 7
    Redd SC. Asthma in the United States: burden and current theories. Environ Health Perspect 2002;110(Suppl. 4):557560.
  • 8
    Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002;109(Suppl. B):S482S489.
  • 9
    Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publication No 02-3659 (issued January 1995, revised 2002). National Institutes of Health/National Heart, Lung, and Blood Institute.; accessed 19 March 2008.
  • 10
    Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802807.
  • 11
    Rabe KF, Adachi M, Lai CK, Soriano JB, Vermiere PA, Weiss KB et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:4047.
  • 12
    Bateman ED, Boushey HA, Bousquet J, Busse W, Clark TJH, Pauwels RA et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 2004;170:836844.
  • 13
    Partridge MR, Van Der MT, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
  • 14
    Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), 2007.; accessed 19 March 2008.
  • 15
    Asthma UK 2004. Where do we stand? Asthma in the UK today.; accessed 19 March 2008.
  • 16
    ENFUMOSA. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:470477.
  • 17
    Rea HH, Scragg R, Jackson R, Beaglehole R, Fenwick J, Sutherland D. A case-control study of deaths from asthma. Thorax 1986;41:833839.
  • 18
    Crane J, Pearce N, Burgess C, Woodman K, Robson B, Beasley R. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992;21:737744.
  • 19
    Guite HF, Dundas R, Burney PGJ. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax 1999;54:301307.
  • 20
    Tough SC, Hessel PA, Ruff M, Green FHY, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657665.
  • 21
    Hartert TV, Speroff T, Togias A, Mitchel EF, Snowden MS, Dittus RS et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002;89:467473.
  • 22
    Dalcin PT, Piovesan DM, Kang S, Fernandes AK, Franciscatto E, Millan T et al. Factors associated with emergency department visits due to acute asthma. Braz J Med Biol Res 2004;37:13311338.
  • 23
    Papiris S, Kotanidou A, Malagari K, Roussos C. Severe asthma. Crit Care 2002;6:3044.
  • 24
    Mohan G, Harrison BD, Badminton RM, Mildenhall S, Wareham NJ. A confidential enquiry into deaths caused by asthma in an English health region: implications for general practice. Br J Gen Pract 1996;46:529532.
  • 25
    Burr ML, Davies BH, Hoare A, Jones A, Williamson IJ, Holgate SK et al. A confidential enquiry into asthma deaths in Wales. Thorax 1999;54:985989.
  • 26
    Watson L, Turk F, James P, Holgate ST. Factors associated with asthma mortality after an asthma admission: a national United Kingdom database analysis. Respir Med 2007;101:16591664.
  • 27
    Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O’Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004;23:287291.
  • 28
    Andersson F, Borg Stahl E. The impact of exacerbations on the asthmatics patients’ preference scores. J Asthma 2003;40:615623.
  • 29
    Schmier J, Leidy NK, Gower R. Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. J Asthma 2003;40:383393.
  • 30
    Turk F, Piercy J, Benford M. The human impact of severe persistent allergic asthma; results of a multinational study. Value Health 2005;8:A32.
  • 31
    Turk F, Kay S, Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Thorax 2005;60(Suppl. II):P21.
  • 32
    Dockrell M, Partridge MR, Valovirta E. The limitations of severe asthma: results of a European survey. Allergy 2007;62:134141.
  • 33
    Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003;58:561566.
  • 34
    Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002;19:6167.
  • 35
    Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:13221326.
  • 36
    Graf von der Schulenburg JM, Greiner W, Molitor S, Kielhorn A. Cost of asthma therapy in relation to severity. An empirical study. Med Klin 1996;91:670676.
  • 37
    Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723729.
  • 38
    Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003;111:12121218.
  • 39
    Van Ganse EV, Antonicelli L, Zhang Q, LaForest L, Yin DD, Nocea G et al. Asthma-related resource use and cost by GINA classification of severity in three European countries. Respir Med 2006;100:140147.
  • 40
    Hoskins G, McCowan C, Thomas G, Smith B, Everhard F. Identifying the characteristics and costs of treating ‘poorly controlled’ asthma patients. Eur Respir Rev 2001;18(Suppl. 33):329s.
  • 41
    McCowan C, Hoskins G, Everhard F, Smith B, Thomas G. Do patients with high-risk asthma suffer increased absenteeism. Am J Respir Crit Care Med 2002;8:A120.
  • 42
    McCowan C, Hoskins G, Thomas G, Everhard F, Smith B, Neville RG. The effect of asthma severity and frequency of attack on health service costs. Am J Respir Crit Care Med 2002;8:A45.
  • 43
    Schwenkglenks M, Lowy A, Anderhub H, Szucs TD. Cost of asthma in a cohort of Swiss adults: associations with exacerbation status and severity. Value Health 2003;6:7583.
  • 44
    Van Ganse E, Laforest L, Pietri G, Boissel JP, Gormand F, Ben-Joseph R et al. Persistent asthma: disease control, resource utilization and direct costs. Eur Respir J 2002;20:260267.
  • 45
    Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE; TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007;62:126133.
  • 46
    Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med 2006;100:434450.
  • 47
    Dewilde S, Rapatz G, Turk F. The cost of asthma exacerbations of different severity levels. Value Health 2005;8:A31.
  • 48
    Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309316.
  • 49
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701708.
  • 50
    Vignola AM, Humbert M, Bousquet J, Boulet L-P, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004;59:709717.
  • 51
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184190.
  • 52
    Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154159.
  • 53
    Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254261 Erratum in: Eur Respir J 2001;18:739–740.
  • 54
    Buhl R, Solèr M, Matz J, Townley R, O’Brien J, Noga O et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:7378.
  • 55
    Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF et al. Efficacy and tolerability of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632638.
  • 56
    Genentech ALTO study.; accessed 19 March 2008.
  • 57
    Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302308.
  • 58
    Dewilde S, Turk F, Tambour M, Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:17651776.
  • 59
    Brown R, Turk F, Iovan S, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma. Allergy 2007;62:149153.
  • 60
    Brown R, Turk F, Groot M, Dale P. Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to The Netherlands. Eur Respir J 2007;30(Suppl. 51):194s.
  • 61
    Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H et al. Predicting and evaluating response to omalizumab in patients with severe persistent allergic asthma. Respir Med 2007;101:14831492.
  • 62
    Niven R, Chung KF, Pandahloo Z, Blogg M, Ayre G. Efficacy of omalizumab in patients with inadequately controlled severe persistent allergic (IgE-mediated) asthma: a subgroup analysis of an open label trial. Allergy 2007;62(Suppl. 83):144, 383.
  • 63
  • 64
    Humbert M, Berger W, Leighton T, Turk F, Hedgecock S, Ayre G et al. Asthma patients judged by the physician to have responded to add-on omalizumab therapy have a greater percentage of symptom-free days. Proceedings of the ATS 2006;3:A591.
  • 65
    Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006;24:11211131.
  • 66
    Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265269.
  • 67
    Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120:11461152.
  • 68
    United States Bureau of Labor Statistics. Consumer Price Index (CPI) detailed report. Washington, DC: US Department of Labor, 2006.
  • 69
    National Institute For Health And Clinical Excellence. Final appraisal determination–omalizumab for severe persistent allergic asthma. 2007.; accessed 19 March 2008.
  • 70
    Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001;108:3946.
  • 71
    Miller MK, Lee JH, Miller DP, Wenzel SE; for the TENOR Study Group. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2006;101:481489.
  • 72
    Slavin R, Fox H, Surrey K, Reisner C. Factors predictive of future clinically significant exacerbations in severe asthma. J Allergy Clin Immunol 2006;117:S274.
  • 73
    Alvarez GG, Schulzer M, Jung D, Fitzgerald JM. A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J 2005;12:265270.
  • 74
    Lowhagen O, Ekstrom L, Holmberg S, Wennerblom B, Rosenfeldt M. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243247.
  • 75
    Campbell JD, Spackman DE, Sullivan SD. Revisiting the cost-effectiveness of omalizumab. Allergy 2007;62:1469.
  • 76
    Bucknall CE, Slack R, Godley CC, Mackay TW, Wright SC. Scottish Confidential Inquiry into Asthma Deaths (SCIAD), 1994–1996. Thorax 1999;54:978984.
  • 77
    Watson L, Turk F, James P, Holgate ST. Factors associated with asthma mortality: a national United Kingdom database analysis. J Allergy Clin Immunol 2007;119(Suppl.):S169.
  • 78
    Natonal Institute for Health and Clinical Excellence. Omalizumab for severe persistent allergic asthma, 2007.; accessed 19 March 2008.
  • 79
    McCoy L, Redelings M, Sorvillo F, Simon P. A multiple cause-of-death analysis of asthma mortality in the United States, 1990–2001. J Asthma 2005;42:757763.
  • 80
    Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006;174:633638.
  • 81
    Clark S, Pelletier AJ, Brenner BE, Lang DM, Strunk RC, Camargo CA. Feasibility of a national fatal asthma registry: more evidence of IRB variation in evaluation of a standard protocol. J Asthma 2006;43:1923.
  • 82
    Novartis Pharmaceutical Canada Inc. Prescribing Information Xolair, 2005 (Revised 2007).; accessed 19 March 2008.
  • 83
    Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 2004;8:iiiiv, ix–x, 1–105.
  • 84
    Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6:1110.
  • 85
    Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:iii, 1–91.
  • 86
    Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:410.
  • 87
    Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:6272.
  • 88
    Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326335.
  • 89
    Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L et al. Infliximab for the treatment of Crohn’s disease: a systematic review and cost-utility analysis. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 2002. Technology report no 24.
  • 90
    Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 2003;7:167.
  • 91
    Jaisson-Hot I, Flouriè B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assessment Health Care 2004;20:274279.
  • 92
    Otten N. Comparison of drug treatments for multiple sclerosis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998.
  • 93
    Kendrick M, Johnson KI. Long term treatment of multiple sclerosis with interferon-β may be cost effective. Pharmacoeconomics 2000;18:4553.
  • 94
    Chilcott J, McCabe C, Tappenden P, O’Hagan A, Cooper NJ, Abrams K et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003;326:522.
  • 95
    Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999;319:15291533.
  • 96
    Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144149.
  • 97
    Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 2002;5:4454.